ECE2023 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (159 abstracts)
Intestinimonas butyriciproducens improves glucose metabolism in subjects with obesity and prediabetes: preliminary data from a randomized controlled trial
Valentina Antoniotti 1 , Marina Caputo 2 , Sabrina TIni 3 , Alessandro Antonioli 3 , Tommaso Daffara 2 , Silvia De Marchi 2 , Elisa Bona 4 , Angela Amoruso 5 , Marco Pane 5 , Sahin Gul 6 , Gianluca Aimaretti 2 , Jos Seegers 6 & Flavia Prodam 2
1SCDU of Pediatrics, Department of Health Sciences, Novara, Italy; 2Endocrinology, Department of Translational Medicine, Novara, Italy; 3Department of Health Sciences, Novara, Italy; 4University of Piemonte Orientale, Department of Sustainable Development and Ecological Transition, Vercelli, Italy; 5Research & Development, Probiotical Research srl, Novara, Italy; 6Caelus Health, Amsterdam, Netherlands
As the prevalence of type 2 Diabetes Mellitus (T2D) is constantly increasing and the current prevention is not enough, new effective strategies are necessary, in particular in high-risk individuals. Therapeutic microbiology is one of further proposed targets, and, in particular, butyrate-producing bacteria can improve metabolic parameters in obese patients. Our study aims to evaluate the effect of Intestinimonas butyriciproducens as a preventive therapy for T2D in prediabetes, since it is able to decrease Advanced Glycation End Products (AGEs), convert sugars and proteins in butyrate, and increase insulin sensitivity. The trial is a double-blind, randomized, placebo-controlled (phase 1) and open label pilot study with two different doses (phase 2). I. butyriciproducens (105 CFU/day) or placebo were given for 12 weeks, then subjects in placebo will start the treatment (105 CFU/day), while the other group will increase the dose (108 CFU/day) for 14 weeks. We included overweight/obese patients with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). Patients were assessed for clinical, biochemical and microbiota parameters at the time of recruitment (V1), after 12 weeks (V7) and 26 weeks of treatment (V10), during which the eating and lifestyle habits were also evaluated. Fourteen out of the 26 patients programmed, have been closed phase 1 and/or 2. In the first 7 patients who completed the study, those who have taken the probiotic since the beginning of the study had a significant improvement in the fasting and post-OGTT glucose-insulin metabolism. In particular, HOMA-index decreased over time in treated patients (V1: 3.3 ± 1.3; V7: 2.6 ± 1.5, V10: 2.5 ± 1.3), whereas remained about unchanged in placebo group (V1: 3.2 ± 1.1, V7: 3.5 ± 1.0, V10: 3.4 ± 1.3). Flash glucose monitoring data were stable. These findings were confirmed in the other 7 patients who completed phase 1. Serum AGE concentrations showed a trend towards a decrease in treated patients. Microbiota analyses are ongoing. In conclusion, Intestinimonas butyriciproducens seems to improve insulin resistance and inflammation in patients treated for a longer period, likely due to the time or dose. Since the study is still ongoing, the data should be confirmed. Intestinimonas butyriciproducens could be a new strategy in the work-up of T2D prevention.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more